By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread

By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs)  A study published this month by NETRF-funded Collaborative Grant

Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.

Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re

In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the

Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks

A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors

Neuroendocrine cancer researchers from around the world gathered in Krakow, Poland for the 22nd Annual ENETS Conference in early March. The European Neuroendocrine Tumor Society

Model systems—whether in vitro (cell lines), ex vivo (organoids), or in vivo (animal models)—are essential for understanding neuroendocrine cancer biology and testing new therapies. However,

In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.”